This is a really interesting study. Worth thinking at a very similar approach for other pathologies for which JAKinibs are a proved therapeutic possibility (RA, SpA, JIA etc.)
#ImmunoSky #Immunology #JAKinibs #JAKi
www.jaad.org/article/S019...

Acne Risk When Treating Atopic Dermatitis With JAK Inhibitors This cohort study evaluates the risk of acne in adult patients with atopic dermatitis who started treatment with Janus kinase inhibitors compared with Th2 cytokine inhibitors.

Increased risk of acne in patients with atopic dermatitis treated with JAK inhibitors. Interesting, risks increased if patients were previously treated with a biologic such as dupilumab.
#JAK #JAKinibs #ImmunoSky #Immunology
jamanetwork.com/journals/jam...

What an honor to be able to present our work at Università Sapienza in Rome today hosted by @sciumelab.bsky.social, while I am here for an month as visiting professor. Amazing experience!
#JAKinibs #Cytokines #ImmunoSky

Not surprised of unexpected positive effects of JAKinibs
#JAK #JAKinibs #ImmunoSky

JAKs, STATs, and New Targets in Inflammatory Skin Disease | Dermatology Times Massimo Gadina, PhD, underscored the need for genetics-guided patient selection to improve treatment specificity in inflammatory skin diseases.

My comments recorded at ISDS 2025 last week in NYC.
#dermatology #jakinibs #inflammation #ImmunoSky

www.dermatologytimes.com/view/jaks-st...

Excited to be a speaker at ISDS 2025. A truly fantastic conference #ImmunoSky
#Jakinibs

Disease modification upon 2 weeks of tofacitinib treatment in a mouse model of chronic epilepsy Brief administration of tofacitinib enduringly suppresses seizures, restores cognition, and dampens astrogliosis in a mouse model of chronic epilepsy.

JAK inhibitors for epilepsy??! WOW I did not see that coming. Tofacitinib does not stop surprising me!
#JAKinibs #ImmunoSky
www.science.org/doi/10.1126/...

Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial This study suggests that, compared with placebo, individuals with polymyalgia rheumatica receiving 4 mg baricitinib are less likely to need oral glucocorticoids to have low disease activity at week 12...

Once again… JAK inhibitors to the rescue!!
#ImmunoSky #JAKinibs
Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial - The Lancet Rheumatology www.thelancet.com/journals/lan...